erlotinib hydrochloride has been researched along with Ovarian Hyperstimulation Syndrome, Familial Gestational Spontaneous in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Galani, V; Georgiou, I; Kitsou, C; Kosmas, IP; Lazaros, L; Markoula, S; Mynbaev, O; Peschos, D; Prapas, I; Prapas, N; Tournaye, H; Zikopoulos, A | 1 |
1 other study(ies) available for erlotinib hydrochloride and Ovarian Hyperstimulation Syndrome, Familial Gestational Spontaneous
| Article | Year |
|---|---|
Everolimus, an mTOR pathway inhibitor, is highly successful on ovarian hyperstimulation syndrome by reducing ovarian weight and progesterone levels: a preclinical experimental randomized controlled study.
Topics: AMP-Activated Protein Kinases; Animals; Capillary Permeability; Chorionic Gonadotropin; Erlotinib Hydrochloride; Everolimus; Female; Follicle Stimulating Hormone; Hormones; Infliximab; Metformin; Organ Size; Ovarian Hyperstimulation Syndrome; Ovary; Progesterone; Protein Kinase Inhibitors; Random Allocation; Rats; Rats, Wistar; Reproductive Control Agents; TOR Serine-Threonine Kinases; Tumor Necrosis Factor-alpha | 2015 |